211 related articles for article (PubMed ID: 19273910)
1. Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid.
Passeron T; Valencia JC; Namiki T; Vieira WD; Passeron H; Miyamura Y; Hearing VJ
J Clin Invest; 2009 Apr; 119(4):954-63. PubMed ID: 19273910
[TBL] [Abstract][Full Text] [Related]
2. Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma.
Cheng PF; Shakhova O; Widmer DS; Eichhoff OM; Zingg D; Frommel SC; Belloni B; Raaijmakers MI; Goldinger SM; Santoro R; Hemmi S; Sommer L; Dummer R; Levesque MP
Genome Biol; 2015 Feb; 16(1):42. PubMed ID: 25885555
[TBL] [Abstract][Full Text] [Related]
3. SOX9 is a dose-dependent metastatic fate determinant in melanoma.
Yang X; Liang R; Liu C; Liu JA; Cheung MPL; Liu X; Man OY; Guan XY; Lung HL; Cheung M
J Exp Clin Cancer Res; 2019 Jan; 38(1):17. PubMed ID: 30642390
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
5. The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation.
Maurus K; Hufnagel A; Geiger F; Graf S; Berking C; Heinemann A; Paschen A; Kneitz S; Stigloher C; Geissinger E; Otto C; Bosserhoff A; Schartl M; Meierjohann S
Oncogene; 2017 Sep; 36(36):5110-5121. PubMed ID: 28481878
[TBL] [Abstract][Full Text] [Related]
6. Targeting the cyclin-dependent kinase 5 in metastatic melanoma.
Sharma S; Zhang T; Michowski W; Rebecca VW; Xiao M; Ferretti R; Suski JM; Bronson RT; Paulo JA; Frederick D; Fassl A; Boland GM; Geng Y; Lees JA; Medema RH; Herlyn M; Gygi SP; Sicinski P
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8001-8012. PubMed ID: 32193336
[TBL] [Abstract][Full Text] [Related]
7. Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma.
Shakhova O; Cheng P; Mishra PJ; Zingg D; Schaefer SM; Debbache J; Häusel J; Matter C; Guo T; Davis S; Meltzer P; Mihic-Probst D; Moch H; Wegner M; Merlino G; Levesque MP; Dummer R; Santoro R; Cinelli P; Sommer L
PLoS Genet; 2015 Jan; 11(1):e1004877. PubMed ID: 25629959
[TBL] [Abstract][Full Text] [Related]
8. Matrin-3 plays an important role in cell cycle and apoptosis for survival in malignant melanoma.
Kuriyama H; Fukushima S; Kimura T; Okada E; Ishibashi T; Mizuhashi S; Kanemaru H; Kajihara I; Makino K; Miyashita A; Aoi J; Okada S; Ihn H; Kita K
J Dermatol Sci; 2020 Nov; 100(2):110-119. PubMed ID: 32943284
[TBL] [Abstract][Full Text] [Related]
9. Clinical, dermoscopic, and confocal features of nevi and melanomas in a multiple primary melanoma patient with the MITF p.E318K homozygous mutation.
Bassoli S; Pellegrini C; Longo C; Di Nardo L; Farnetani F; Cesinaro AM; Pellacani G; Fargnoli MC
Melanoma Res; 2018 Apr; 28(2):166-169. PubMed ID: 29485552
[No Abstract] [Full Text] [Related]
10. SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation.
Wang J; Yang Z; Wen J; Ma F; Wang F; Yu K; Tang M; Wu W; Dong Y; Cheng X; Nie C; Chen L
J Pharmacol Sci; 2014; 126(3):198-207. PubMed ID: 25341684
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.
Kato Y; Salumbides BC; Wang XF; Qian DZ; Williams S; Wei Y; Sanni TB; Atadja P; Pili R
Mol Cancer Ther; 2007 Jan; 6(1):70-81. PubMed ID: 17237267
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of SOX9 in lung adenocarcinoma and its involvement in the regulation of cell growth and tumorigenicity.
Jiang SS; Fang WT; Hou YH; Huang SF; Yen BL; Chang JL; Li SM; Liu HP; Liu YL; Huang CT; Li YW; Jang TH; Chan SH; Yang SJ; Hsiung CA; Wu CW; Wang LH; Chang IS
Clin Cancer Res; 2010 Sep; 16(17):4363-73. PubMed ID: 20651055
[TBL] [Abstract][Full Text] [Related]
13. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.
Epping MT; Wang L; Edel MJ; Carlée L; Hernandez M; Bernards R
Cell; 2005 Sep; 122(6):835-47. PubMed ID: 16179254
[TBL] [Abstract][Full Text] [Related]
14. CYR61 suppresses growth of human malignant melanoma.
Chen J; Liu Y; Sun Q; Wang B; Li N; Chen X
Oncol Rep; 2016 Nov; 36(5):2697-2704. PubMed ID: 27665942
[TBL] [Abstract][Full Text] [Related]
15. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
Goel VK; Ibrahim N; Jiang G; Singhal M; Fee S; Flotte T; Westmoreland S; Haluska FS; Hinds PW; Haluska FG
Oncogene; 2009 Jun; 28(23):2289-98. PubMed ID: 19398955
[TBL] [Abstract][Full Text] [Related]
16. Nucleosome assembly protein 1-like 4, a new therapeutic target for proliferation and invasion of melanoma cells.
Mizuhashi S; Fukushima S; Ishibashi T; Kuriyama H; Kimura T; Kanemaru H; Kajihara I; Makino K; Miyashita A; Aoi J; Kita K; Ihn H
J Dermatol Sci; 2021 Apr; 102(1):16-24. PubMed ID: 33583643
[TBL] [Abstract][Full Text] [Related]
17. Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and β-catenin pathways.
Chiu CS; Tsai CH; Hsieh MS; Tsai SC; Jan YJ; Lin WY; Lai DW; Wu SM; Hsing HY; Arbiser JL; Sheu ML
Cancer Lett; 2019 Feb; 442():113-125. PubMed ID: 30391358
[TBL] [Abstract][Full Text] [Related]
18. A novel stilbene-like compound that inhibits melanoma growth by regulating melanocyte differentiation and proliferation.
Stueven NA; Schlaeger NM; Monte AP; Hwang SL; Huang CC
Toxicol Appl Pharmacol; 2017 Dec; 337():30-38. PubMed ID: 29042215
[TBL] [Abstract][Full Text] [Related]
19. Identification of a small molecule that downregulates MITF expression and mediates antimelanoma activity in vitro.
Cheng C; Yang HW; Shang JF; Li WW; Sun QZ; Chen X; Cao ZX; Yao SH; Yang SY
Melanoma Res; 2016 Apr; 26(2):117-24. PubMed ID: 26684062
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF.
Anghel SI; Correa-Rocha R; Budinska E; Boligan KF; Abraham S; Colombetti S; Fontao L; Mariotti A; Rimoldi D; Ghanem GE; Fisher DE; Lévy F; Delorenzi M; Piguet V
Pigment Cell Melanoma Res; 2012 Jul; 25(4):482-7. PubMed ID: 22594792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
